A post by @FirstSquawk on X.
PFIZER TO LICENSE THREE CAR-T PROGRAMS FROM CHINA'S STARNA FOR $330 MILLION UPFRONT
@FirstSquawk on X
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Pfizer will pay $330 million upfront to license three CAR-T cell therapy programs from Chinese biotech STARNA, according to a First Squawk tweet. The deal covers three CAR-T candidates and marks another instance of a large multinational pharma company looking to China for early-stage cell therapy assets. The upfront figure is notable relative to typical early-stage licensing deals, though the tweet did not disclose the total deal value including milestones. The agreement matters because it signals continued appetite among global drugmakers for Chinese oncology innovation amid cost pressures on domestic pipelines. What to watch next: confirmation of the full deal terms, including milestone payments and royalties, and details on the specific CAR-T targets and development timelines.
Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.
Named in this story
Pfizer (PFE), Starna, CAR-T programs
A linked name opens that asset's sentiment page.